Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 6/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluoride SCHEMBL1633903 | 0.98 | ACHE (0.44) | ACHEMAPTALDH1A1POLBKDM4E | |
| SCHEMBL28183847 | 0.84 | ALDH1A1 (0.44) | MAPTALDH1A1POLBKDM4EGFER | |
| SCHEMBL28958866 | 0.79 | ACHE (0.42) | ACHEMAPTALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL16707585 | 0.77 | ALDH1A1 (0.46) | ACHEMAPTALDH1A1POLBGFER | |
| SCHEMBL23554066 | 0.74 | DDB1 (0.45) | MAPTALDH1A1POLBL3MBTL1DDB1 | |
| SCHEMBL14409994 | 0.74 | ALDH1A1 (0.38) | MAPTALDH1A1POLBGFERHTT | |
| SCHEMBL6245615 | 0.74 | KMT2A (0.39) | MAPTALDH1A1POLBKDM4EL3MBTL1 | |
| SCHEMBL13764455 | 0.74 | ALDH1A1 (0.38) | MAPTALDH1A1POLBKDM4EGFER | |
| SCHEMBL11056267 | 0.74 | CYP3A4 (0.46) | MAPTALDH1A1POLBKDM4EMAPK1 | |
| SCHEMBL14257328 | 0.74 | HAO1 (0.43) | ACHEMAPTALDH1A1POLBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117843276-B | Multi-component composite steel slag grinding-aid excitant and preparation method thereof | 华新水泥股份有限公司 | 2024-11-26 | — | — | CN | claimed |
| CN-117843276-B | Multi-component composite steel slag grinding-aid excitant and preparation method thereof | 华新水泥股份有限公司 | 2024-11-26 | — | — | CN | disclosed |
| CN-117843276-A | Multi-component composite steel slag grinding-aid excitant and preparation method thereof | 华新水泥股份有限公司 | 2024-04-09 | — | — | CN | disclosed |
| EP-3252045-B1 | CYANOGUANIDINES AND THEIR USE AS ANTIVIRAL AGENTS | ABBVIE INC (US) | 2019-09-04 | — | — | EP | disclosed |
| CN-107235875-B | A method of synthesis 1,2,2- trifluoro-ethylene sulfide compound | 福州大学 | 2019-02-22 | — | — | CN | disclosed |
| EP-2867221-B1 | CYANOGUANIDINES AND THEIR SUE AS ANTIVIRAL AGENTS. | ABBVIE INC (US) | 2018-01-17 | — | — | EP | disclosed |
| EP-3252045-A1 | CYANOGUANIDINES AND THEIR USE AS ANTIVIRAL AGENTS | AbbVie Inc. (US) | 2017-12-06 | — | — | EP | disclosed |
| CN-107235875-A | A kind of method for synthesizing 1,2,2 trifluoro-ethylene sulfide compounds | 福州大学 | 2017-10-10 | — | — | CN | disclosed |
| EP-2313407-B1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2016-10-05 | — | — | EP | disclosed |
| US-8178534-B2 | cMET inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-15 | — | — | US | disclosed |
| US-8178534-B2 | cMET inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-15 | — | — | US | disclosed |
| WO-2012003338-A1 | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-05 | — | — | WO | disclosed |
| US-20100063054-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100063054-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-11 | — | — | US | disclosed |
| WO-2010019899-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | WO | disclosed |
| CN-1214049-C | Process for producing ethylene/olefin interpolymers | EASTMAN CHEM CO (US) | 2005-08-10 | — | — | CN | disclosed |
| CN-1367798-A | Process for producing ethylene/olefin interpolymers | EASTMAN CHEM CO (US) | 2002-09-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063054-A1 | cMET INHIBITORS | CEPT1, LCAT, GNMT | ACHE 740/4885MAPT 235/4885ALDH1A1 3166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.